Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-weekly BAY 79-4980 versus three-times-weekly Kogenate Bayer prophylaxis in severe hemophilia A
2007-003718-32Phase 2Completed
- Sponsor
- Bayer
- Start
- Nov 2007
- Modality
- Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in hemophilia A comparing Once-weekly BAY 79-4980 prophylaxis with Three-times-weekly Kogenate Bayer prophylaxis (2 arms). Primary endpoint: Subjects with fewer than 9 total bleeds per year. Started Nov 2007; status: completed.
02
Drugs
BAY 79-4980Factor VIII
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2007-003718-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003718-32.